leisure time -WSS

leisure time

author：focus 2025-09-29 18:02:11 - browse：21

To much of the public, the promise of telehealth is all about convenience — get the prescription you need quickly, and get it delivered right to your door. But as digital health companies build out their weight loss businesses, capitalizing on the popularity of drugs like Wegovy and Ozempic, they’re courting a very different audience: payers and employers who have a vested interest in preventing quick scripts.

Payers are reeling as they try to figure out how to sustainably cover GLP-1 receptor agonists, a class of remarkably effective but expensive obesity and type 2 diabetes drugs. So in the last six months, digital health companies including Teladoc, Found, Hello Alpha, and Calibrate have advanced enterprise products that pair virtual visits and prescriptions with lifestyle coaching. Their hope is that more and more payers and employers will offer their programs as a way to support lasting weight loss and metabolic health — or even require them if patients want their drugs reimbursed.

The competition is growing quickly. Telehealth companies once focused exclusively on consumers are now marketing to payers. Enterprise programs for chronic care management are promoting new services to support patients on obesity drugs. And companies like Noom and WeightWatchers, which have built gargantuan weight loss businesses for consumers and businesses alike, are starting to prescribe the drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

WSS

Making the case for fair compensation in clinical trials

ASCO eve: Let’s set the table for this year's meeting

Hormonal contraceptives don’t actually treat endometriosis

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Caribou posts encouraging results on off

https://cbu01.alicdn.com/img/ibank/2017/701/385/4166583107_1695841539.220x220xz.jpg

explore

leisure time

entertainment

The cancer drug shortage isn’t new — and neither are the solutions

Scrutiny of post

Duchenne breakthrough therapy leaves behind pioneering families

Caribou posts encouraging results on off

Hepatitis C has a cure — but many Americans still lack access to it

US jobless claims fall again as labor market continues to flash strength

DIEP, the 'gold standard' of breast reconstruction, is under threat

Cue Health, Covid

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Eli Lilly to acquire DICE Therapeutics in $2.4 billion deal

hotspot

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

H5N1 bird flu outbreak: Second human case reported, in Michigan

H5N1 virus can be tracked in retail milk, scientists say

Investigation reveals sickle cell patients pressured into sterilizations

FDA poised to publish guidelines for clinical trial diversity

Study finds gene variants tied to breast cancer risk in Black women

focus

entertainment

explore

focus